TY - JOUR
T1 - Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer
T2 - Approach to subtyping progressive disease and clinical implications
AU - Gandara, David R
AU - Li, Tianhong
AU - Lara, Primo N
AU - Kelly, Karen
AU - Riess, Jonathan
AU - Redman, Mary W.
AU - Mack, Philip
PY - 2014/1
Y1 - 2014/1
N2 - In the emerging era of targeted therapy for advanced-stage non-small-cell lung cancer, it is becoming increasingly important to anticipate underlying driver oncogene alterations at the time of initial diagnosis and tumor-tissue acquisition, so that patients can be selected in a timely fashion for first-line tyrosine kinase inhibitor (TKI) therapy if their cancers are found to harbor tyrosine-kinase-activating mutations in the epidermal growth factor receptor gene or gain-of-function rearrangements in the anaplastic lymphoma kinase gene. However, despite the clear benefits of TKI therapy over chemotherapy in these settings, the eventual emergence of acquired resistance and progressive disease (PD) is universal. How to best approach oncogene-driven non-small-cell lung cancer at the time of acquired resistance to initial TKI therapy is an increasingly complex question because of variability in mechanisms of resistance, extent of PD, and inter- and intrapatient tumor heterogeneity. Here we propose an approach to subtyping PD in the setting of acquired resistance as well as subsequent clinical implications.
AB - In the emerging era of targeted therapy for advanced-stage non-small-cell lung cancer, it is becoming increasingly important to anticipate underlying driver oncogene alterations at the time of initial diagnosis and tumor-tissue acquisition, so that patients can be selected in a timely fashion for first-line tyrosine kinase inhibitor (TKI) therapy if their cancers are found to harbor tyrosine-kinase-activating mutations in the epidermal growth factor receptor gene or gain-of-function rearrangements in the anaplastic lymphoma kinase gene. However, despite the clear benefits of TKI therapy over chemotherapy in these settings, the eventual emergence of acquired resistance and progressive disease (PD) is universal. How to best approach oncogene-driven non-small-cell lung cancer at the time of acquired resistance to initial TKI therapy is an increasingly complex question because of variability in mechanisms of resistance, extent of PD, and inter- and intrapatient tumor heterogeneity. Here we propose an approach to subtyping PD in the setting of acquired resistance as well as subsequent clinical implications.
UR - http://www.scopus.com/inward/record.url?scp=84891829967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891829967&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2013.10.001
DO - 10.1016/j.cllc.2013.10.001
M3 - Article
C2 - 24176733
AN - SCOPUS:84891829967
VL - 15
SP - 1
EP - 6
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
SN - 1525-7304
IS - 1
ER -